CN102482210B - 维生素d受体激动剂及其用途 - Google Patents

维生素d受体激动剂及其用途 Download PDF

Info

Publication number
CN102482210B
CN102482210B CN201080027380.8A CN201080027380A CN102482210B CN 102482210 B CN102482210 B CN 102482210B CN 201080027380 A CN201080027380 A CN 201080027380A CN 102482210 B CN102482210 B CN 102482210B
Authority
CN
China
Prior art keywords
compound
vida
ethyl
ylidene
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080027380.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102482210A (zh
Inventor
河合惠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cinkate Pharmaceutical Intermediates Co ltd
Original Assignee
VIDASYM Inc
VIDASYM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIDASYM Inc, VIDASYM LLC filed Critical VIDASYM Inc
Publication of CN102482210A publication Critical patent/CN102482210A/zh
Application granted granted Critical
Publication of CN102482210B publication Critical patent/CN102482210B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/50—Spiro compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201080027380.8A 2009-04-17 2010-04-12 维生素d受体激动剂及其用途 Active CN102482210B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17016009P 2009-04-17 2009-04-17
US61/170,160 2009-04-17
PCT/US2010/030777 WO2010120698A1 (en) 2009-04-17 2010-04-12 Vitamin d receptor agonists and uses thereof

Publications (2)

Publication Number Publication Date
CN102482210A CN102482210A (zh) 2012-05-30
CN102482210B true CN102482210B (zh) 2015-04-08

Family

ID=42710758

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080027380.8A Active CN102482210B (zh) 2009-04-17 2010-04-12 维生素d受体激动剂及其用途

Country Status (8)

Country Link
US (2) US20120115824A1 (cg-RX-API-DMAC7.html)
EP (1) EP2419403B1 (cg-RX-API-DMAC7.html)
JP (1) JP5665848B2 (cg-RX-API-DMAC7.html)
CN (1) CN102482210B (cg-RX-API-DMAC7.html)
AU (1) AU2010236642B2 (cg-RX-API-DMAC7.html)
CA (1) CA2758698C (cg-RX-API-DMAC7.html)
NZ (1) NZ595727A (cg-RX-API-DMAC7.html)
WO (1) WO2010120698A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993547B2 (en) * 2011-06-14 2015-03-31 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses
CN105456278A (zh) * 2014-09-03 2016-04-06 欣凯医药科技(上海)有限公司 一种抑制食欲的活性维生素d类似物
CN105384765A (zh) * 2014-09-04 2016-03-09 欣凯医药科技(上海)有限公司 奎宁酸内酯衍生物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004085A1 (en) * 2003-07-03 2005-01-06 Deluca Hector F. 2-Methylene-19-nor-20(S)-25-methyl-1alpha-hydroxycalciferol and its uses
EP1559708A1 (en) * 2002-10-10 2005-08-03 Masato Shimizu 2,2-DI-SUBSTITUTED 1a,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE
WO2009067578A2 (en) * 2007-11-20 2009-05-28 Abbott Laboratories New vitamin d receptor activators and methods of making

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1559708A (en) * 1924-04-11 1925-11-03 Kelsey Walter Harrison Mattress and method of making the same
JP3759639B2 (ja) * 1994-04-11 2006-03-29 中外製薬株式会社 22−チアビタミン▲d3▼誘導体
JPH10182597A (ja) * 1996-10-29 1998-07-07 Sumitomo Pharmaceut Co Ltd 異性化ビタミンd誘導体
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
WO1998052574A1 (en) * 1997-05-22 1998-11-26 Cephalon, Inc. Vitamin d analogues and their neuronal effects
GB9819764D0 (en) * 1998-09-10 1998-11-04 Oxagen Limited Method
IT1311921B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US6673782B2 (en) * 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
WO2004067504A1 (ja) * 2003-01-31 2004-08-12 Chugai Seiyaku Kabushiki Kaisha 2位置換ビタミンd誘導体
US20050209203A1 (en) * 2003-07-30 2005-09-22 Jin Tian Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1559708A1 (en) * 2002-10-10 2005-08-03 Masato Shimizu 2,2-DI-SUBSTITUTED 1a,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE
US20050004085A1 (en) * 2003-07-03 2005-01-06 Deluca Hector F. 2-Methylene-19-nor-20(S)-25-methyl-1alpha-hydroxycalciferol and its uses
WO2009067578A2 (en) * 2007-11-20 2009-05-28 Abbott Laboratories New vitamin d receptor activators and methods of making

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Crystal Structures of Rat Vitamin D Receptor Bound to Adamantyl Vitamin D Analogs:Structural Basis for Vitamin D Receptor Antagonism and Partial Agonism;Makoto Nakabayashi et al.;《J. Med. Chem.》;20080819;第51卷(第17期);5320–5329 *
Molecular Evaluation of Vitamin D3 Receptor Agonists Designed for Topical Treatment of Skin Diseases;Yvonne Bury et al.;《THE JOURNAL OF INVESTIGATIVE DERMATOLOGY》;20010531;第116卷(第5期);785-792 *
Synthesis and biological activities of new 1α,25-dihydroxy-19-norvitamin D3 analogs with modifications in both the A-ring and the side chain;Masato Shimizu et al.;《Bioorganic & Medicinal Chemistry》;20060224;第14卷;4277–4294 *

Also Published As

Publication number Publication date
JP2012524091A (ja) 2012-10-11
NZ595727A (en) 2013-11-29
CA2758698C (en) 2017-08-08
CA2758698A1 (en) 2010-10-21
JP5665848B2 (ja) 2015-02-04
WO2010120698A1 (en) 2010-10-21
AU2010236642A1 (en) 2011-11-03
CN102482210A (zh) 2012-05-30
US20180327354A1 (en) 2018-11-15
EP2419403A1 (en) 2012-02-22
US20120115824A1 (en) 2012-05-10
AU2010236642B2 (en) 2014-06-26
EP2419403B1 (en) 2016-09-07
HK1166493A1 (zh) 2012-11-02

Similar Documents

Publication Publication Date Title
JP5544298B2 (ja) 新規ビタミンd受容体賦活剤および製造方法
US7531527B2 (en) 2-Propylidene-19-nor-vitamin D compounds
JP2006096759A (ja) 2−アルキル−19−ノル−ビタミンd化合物
JP2001504135A (ja) 2−アルキリデン−19−ノル−ビタミンd化合物
KR100593238B1 (ko) 비타민 d3 유도체 및 이로부터 제조된 염증성 호흡기 질환 치료제
US20180327354A1 (en) Unnatural Analogues of Calcitriol and Uses Thereof
JP2008515978A (ja) カンナビネルジック脂質リガンド
JP2001505527A (ja) ピリジル置換されたc▲下13▼側鎖を有するタキサン誘導体、その製造方法および抗腫瘍剤としてのその使用
JPWO2010053165A1 (ja) ビタミンd3ラクタム誘導体
JPWO1999043645A1 (ja) 24−ヒドロキシビタミンd誘導体
HK1166493B (en) Vitamin d receptor agonists and uses thereof
JPH11500112A (ja) 新規のボルネオール誘導体、その製造方法及び薬剤学的使用
HUT77669A (hu) 18-Nor-D-vitamin vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EP1219599B1 (en) Vitamin d derivatives having substituents at the 2 alpha-position
JP2003519682A (ja) 新規ビタミンd類似体
KR20150054011A (ko) 9,10-세코프레그난 유도체 및 의약
EP0971916A1 (fr) Derives de n-(arginyl)benzenesulfonamide et leur utilisation comme agents antithrombotiques
HK1086817B (en) 2- propylidene-19-nor-vitamin d compounds
ITMI950032A1 (it) Composti arilalchilenici
JPWO2000064870A1 (ja) 3−メチルビタミンd誘導体
JPWO2001016099A1 (ja) 2α位に置換基を有するビタミンD誘導体
JPWO2000038692A1 (ja) ビタミンd3誘導体を用いる嚢胞性線維症治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: VIDASYM CORP.

Free format text: FORMER OWNER: VIDASYM LLC

Effective date: 20130614

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130614

Address after: Illinois USA

Applicant after: Vidasym, Inc.

Address before: Illinois USA

Applicant before: VIDASYM, LLC

C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20120530

Assignee: CINKATE PHARM TECH (SHANGHAI) Co.,Ltd.

Assignor: Vidasym, Inc.

Contract record no.: 2015990000973

Denomination of invention: Vitamin d receptor agonists and uses thereof

Granted publication date: 20150408

License type: Exclusive License

Record date: 20151120

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
TR01 Transfer of patent right

Effective date of registration: 20210531

Address after: Building 7, Lane 720, Cailun Road, Zhangjiang hi tech, Pudong New Area, Shanghai

Patentee after: CINKATE PHARM TECH (SHANGHAI) Co.,Ltd.

Address before: Illinois USA

Patentee before: Vidasym, Inc.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230412

Address after: 201203 3rd floor, building 3, Lane 67, libing Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee after: CINKATE PHARMACEUTICAL INTERMEDIATES Co.,Ltd.

Address before: Building 7, Lane 720, Cailun Road, Zhangjiang High Tech, Pudong New Area, Shanghai, March 2012

Patentee before: CINKATE PHARM TECH (SHANGHAI) Co.,Ltd.

TR01 Transfer of patent right